Biogen BIIB LEQEMBI Collaboration — Share of non-controling interest recognized

Similar metrics at other companies

TMHCNoncontrolling Interest In Net Income Loss Joint Venture Partners Redeemable

$1.8M+581%

CBLNoncontrolling Interest In Net Income Loss Operating Partnerships Redeemable

$8K+33.3%

AATNoncontrolling Interest In Net Income Loss Operating Partnerships Redeemable

$1.37M-88.0%

XOMNon-U.S. — Net income (loss) attributable to noncontrolling interests

$243M-18.5%

VNONoncontrolling Interest in Net Income (Loss) Joint Venture Partners, Nonredeemable

-$12.69M-21.6%

RLJNoncontrolling Interest in Net Income (Loss) Joint Venture Partners, Nonredeemable

-$174K-0.6%

Questions, answered.

What is Biogen's LEQEMBI collaboration — share of non-controling interest recognized?

Biogen (BIIB) reported LEQEMBI collaboration — share of non-controling interest recognized of 50% in Q4 2025.

What does LEQEMBI collaboration — share of non-controling interest recognized mean?

This metric represents the portion of net income or loss attributable to non-controlling interests within a specific collaborative arrangement for a pharmaceutical product. It reflects the economic interest held by external partners in the joint venture or co-development structure. This figure is essential for understanding the net economic benefit retained by the company versus the portion owed to collaboration partners.